Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 321,385	$ 336,326
Grants receivable	1,241	133
Research and development tax credits receivable		192
Prepaid expenses and other current assets	2,293	2,893
Total current assets	324,919	339,544
Property and equipment, net	1,350	1,352
Research and development tax credits receivable	3,153	3,286
Restricted cash	138	128
Right of use asset	3,046
Other assets	283	248
Total assets	332,889	344,558
Current liabilities:
Accounts payable	5,300	3,026
Accrued expenses and other current liabilities	5,314	7,486
Deferred income	666	4,486
Lease liability	550
Total current liabilities	11,830	14,998
Grants repayable	5,642	5,883
Other noncurrent liabilities	305	480
Lease liability, net of current portion	2,503
Total liabilities	20,280	21,361
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; zero shares issued or outstanding at March 31, 2021 and December 31, 2020
Common stock, $0.001 par value, 150,000,000 shares authorized; 35,100,999 and 35,044,758 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	35	35
Additional paid-in capital	399,694	396,443
Accumulated other comprehensive income	312	617
Accumulated deficit	(87,432)	(73,898)
Total stockholders’ equity	312,609	323,197
Total liabilities, redeemable convertible preferred stock and stockholders’ equity	$ 332,889	$ 344,558